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Summary
Autosomal recessive Alport syndrome is a progressive
hematuric glomerulonephritis characterized by glome-
rular basement membrane abnormalities and associated
with mutations in either the COL4A3 or the COL4A4
gene, which encode the a3 and a4 type IV collagen
chains, respectively. To date, mutation screening in the
two genes has been hampered by the lack of genomic
structure information. We report here the complete char-
acterization of the 48 exons of the COL4A4 gene, a
comprehensive gene screen, and the subsequent detec-
tion of 10 novel mutations in eight patients diagnosed
with autosomal recessive Alport syndrome. Further-
more, we identified a glycine to alanine substitution in
the collagenous domain that is apparently silent in the
heterozygous carriers, in 11.5% of all control individ-
uals, and in one control individual homozygous for this
glycine substitution. There has been no previous finding
of a glycine substitution that is not associated with any
obvious phenotype in homozygous individuals.
Introduction
Type IV collagen forms the basic structural component
of basement membranes. There are six different type IV
collagen chains, named a1–a6, which are encoded by
distinct but highly homologous genes (Hudson et al.
1993). The genes are unique in that they have charac-
teristic pairwise, head-to-head chromosomal arrange-
ments. These arrangements are the result of evolution
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by the intrachromosomal and subsequent interchro-
mosomal duplication of a common ancestral gene, and
they can allow coordinated regulation of a particular
gene pair. The genes of each pair can be divided, by their
homology, into two classes, the COL4A1- or COL4A2-
like genes, thus defining their evolutionary origin (Zhou
et al. 1994). The corresponding a chains may assemble
into various different heterotrimers to produce different
functional isoforms. The a1 and a2 chains are known
to form (a1)2a2 trimers and are ubiquitously coex-
pressed in all basement membranes (Timpl 1989),
whereas the other chains have more restricted tissue-
specific expression patterns (Kleppel et al. 1989; Ni-
nomiya et al. 1995; Peissel et al. 1995). The a3, a4, and
a5 chains are strongly expressed in the glomerular base-
ment membrane (GBM) (Peissel et al. 1995; Ninomiya
et al. 1995).
The hereditary nephritis Alport syndrome (AS) (MIM
104200), a progressive, hematuric glomerulonephritis
often associated with sensorineural hearing loss and spe-
cific eye lesions, is a predominantly X-linked condition
characterized by GBM abnormalities (Atkin et al. 1988),
and many cases have been shown to be due to mutations
in the X chromosome–located COL4A5 gene (Barker et
al. 1990; Knebelmann et al. 1996; Lemmink et al. 1997).
However, up to 15% of AS cases are autosomally in-
herited and are thought to be due to mutations in the
COL4A3 and COL4A4 genes, which are located on
chromosome 2 (Mariyama et al. 1992). In addition, au-
tosomal dominant forms of AS and dominantly inherited
familial benign hematuria (FBH) (MIM 141200) have
been shown to be linked to the COL4A3-COL4A4 locus,
which identifies these as a spectrum of disorders with
similar underlying pathology (Lemmink et al. 1996; Jef-
ferson et al. 1997). Mutation screening in these two
genes to evaluate their involvement in the molecular eti-
ology of such disorders has been hampered by the avail-
ability of only partial intron-exon structure of the genes.
To date, only five COL4A3 mutations (Mochizuki et al.
1994; Lemmink et al. 1994; Ding et al. 1995; Knebel-
mann et al. 1995) and two COLA4A4 mutations (Moch-
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izuki et al. 1994) have been reported in autosomal re-
cessive AS, and only one COL4A4 mutation (Lemmink
et al. 1996) in familial benign hematuria.
The human COL4A4 cDNA is translated into a
1,690–amino acid polypeptide, which consists of a 38-
residue signal peptide, a 1,421-residue collagenous do-
main, and a 231-residue noncollagenous (NC1) domain
(Leinonen et al. 1994). Only 6 exons at the 3′ end have
been characterized (Kamagata et al. 1992; Sugimoto et
al. 1993; Mochizuki et al. 1994). More recently, the
organization of the 5′ end has been determined (Momota
et al. 1998). We report here the complete characteriza-
tion of the COL4A4 gene structure, and we demonstrate
the usefulness of this information by the detection of 10
novel mutations in eight patients diagnosed with auto-
somal recessive AS.
Patients and Methods
Patients
Thirty-one unrelated autosomal recessive AS patients
of European (21), North African (6), Middle Eastern
(2), and West Indian (2) origin were investigated. All
fulfilled the diagnostic criteria for AS (Antignac et al.
1994), and autosomal recessive inheritance was assessed
on the existence of one or more of the following: (1)
severity of the disease in young females, (2) consan-
guinity in the family, (3) microscopic hematuria in the
father of a male patient, (4) immunohistochemical
changes typical of autosomal recessive AS (Gubler et al.
1995), and (5) exclusion of linkage to the COL4A5 lo-
cus. Informed consent was obtained from all individuals
or their parents. A control group was composed of 48
individuals with no obvious phenotype. The group com-
prised 34 Europeans, 8 North Africans, 2 Africans, and
4 individuals from the Middle East.
Long-Range PCR Amplification
Twenty 18–20-base primer pairs located ∼250 nucle-
otides apart were chosen at random to cover the entire
5.2-kb COL4A4 cDNA sequence (Leinonen et al. 1994),
by means of the OLIGO 5.0 program (NBI). The primers
were used to amplify COL4A4 genomic DNA from the
YAC 929_G_1 from the CEPH library. We amplified∼50
ng of total yeast DNA from melted YAC plugs, using
the Expand Long Template PCR System (Boehringer
Mannheim) according to the manufacturer’s protocol.
The 10# buffer containing 22.5 mM MgCl2 and opti-
mized for amplifying the largest templates was used. The
PCR reaction was performed with a GeneAmp PCR Sys-
tem 9600 (Perkin-Elmer) under the following conditions
(Rozet et al. 1996): an initial denaturation step at 94C
for 4 min; 10 cycles of denaturation at 93C for 10 s
and annealing/extension at 59C for 15 s; 20 cycles of
denaturation at 93C for 10 s and annealing/extension
at 59C for 15 min, with a 20 s/cycle stepwise augmen-
tation of the annealing/extension time; and a final ex-
tension step at 68C for 10 min. Failure to obtain an
amplification product under these conditions, followed
by less stringent annealing temperature conditions, was
thought to indicate either the presence of one or more
large introns (112 kb) or the presence of an exon-exon
boundary within one or both of the primer sequences.
To rectify this problem, we took advantage of the high
homology between type IV collagen chains and rede-
signed primers outside putative exon-exon boundaries,
modeled on the mouse col4a2 genomic structure (Buttice
et al. 1990). The amplification products were purified
with either the Geneclean II kit (Bio 101) or the Wizard
PCR Preps DNA purification system (Promega). Purified
fragments were sequenced directly, with specific primers
for the cDNA or the genomic sequence and the PRISM
Ready Reaction Sequencing kit (Perkin-Elmer) on an au-
tomatic fluorometric DNA sequencer (Perkin-Elmer).
Ligation-Mediated PCR
To characterize the structures of the exons, which were
inaccessible by long-range PCR amplification because of
the presence of very large introns, we designed a series
of external and internal primers in specific regions of
interest (i.e., within an exon with an undefined exon-
intron boundary and directed toward the potential
boundary). We thereby characterized the intervening ge-
nomic sequences by ligation-mediated PCR, using the
technique described by Kere et al. (1992), replacing
YAC-arm primers with region-specific primers. Ampli-
fication products were purified and sequenced as de-
scribed above.
Mutation Detection by SSCP Analysis and Direct
Sequencing
We amplified all coding exons by PCR using flanking
intronic primers selected with the OLIGO 5.0 program
(NBI) and screened by SSCP analysis, as described else-
where (Saunier et al. 1997). Where mobility shifts were
detected, automated direct sequencing was used to char-
acterize the sequence variation. SSCP analysis and direct
sequencing were used to detect and to evaluate the pres-
ence of the nucleotide variants in the control population.
Results
Intron-Exon Structure Determination
Three YAC clones from the human CEPH library (Co-
hen et al. 1993) containing at least part of the COL4A4
gene—clones 870_B_6 (400 kb), 929_G_1 (1220 kb),
and 933_C_7 (1690 kb)—were found by screening Uni-
gene, a gene-oriented view of European Molecular Bi-
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ology Laboratory/GenBank sequence entries at the Na-
tional Center for Biotechnology Information, and the
STS-based map of the human genome at the Whitehead
Institute for Biomedical Research/MIT Center for Ge-
nome Research. 929_G_1 was shown, by PCR and
Southern blot analysis, to contain the 3′ ends of both
COL4A3 and COL4A4 and thus was chosen for use in
the study. Long-range PCR amplification of YAC ge-
nomic DNA, using randomly chosen cDNA PCR prim-
ers in combination with ligation-mediated PCR, allowed
identification of a total of 48 individual exons covering
the COL4A4 cDNA sequence. All of these had recog-
nizable 3′ and 5′ splice sites conforming to the GT-AG
rule for intron-exon boundaries, except for the 5′ splice
site of exon 21 (see table 1). The sizes of the coding
exons range from 9 bp to 287 bp. The initiation me-
thionine codon is in exon 2, and the signal peptide is
encoded by exons 2 and 3. Exons 4–45 and the 5′ part
of exon 46 code for the collagenous domain. The car-
boxyl NC1 domain is encoded by the 3′ end of exon 46,
exon 47, and the coding part of exon 48. PCR ampli-
fication of the YAC DNA as well as various human
control DNAs, using primers located in the 3′ untran-
slated region (5452F: 5′-ATGCTGCACAGATGGAT-
TTG-3′ and 5569R: 5′-TGGCCTTTATCATCTACTTG-
3′), consistently give a 137-bp fragment, which proves
that this region is entirely encoded by a single exon (48).
The exons, their sizes, the immediately flanking intronic
sequences, and the approximate intron sizes are indi-
cated in table 1. All sequences derived from YAC ge-
nomic DNA were confirmed on human genomic DNA,
and no exonic deletions were found in the YAC.
As expected, comparison of the deduced COL4A4
gene structure, with respect to exon number and size,
with the other previously characterized type IV collagen
genes revealed a high degree of similarity to the X-linked
COL4A6 gene, as well as to mouse col4a2, as is shown
in figure 1. Twenty-five COL4A4 exons are the same size
as the corresponding COL4A6 exons, and 19 of them
are also the same size as the corresponding mouse col4a2
exons. As with COL4A5 and COL4A6, the first several
exons (5–18) of the collagenous domain and three other
exons (23, 25, and 34) begin with an intact glycine co-
don, whereas the remaining 25 exons encoding the col-
lagenous domain start with the second nucleotide of a
glycine codon.
SSCP Mutation Analysis
PCR primers designed for SSCP screening are indi-
cated in table 2. SSCP screening of all the coding exons
allowed the detection of multiple band shifts. In eight
cases (exons 17, 21, 29, 33, 39, 42, 44, and 47), highly
variable patterns were observed among patients and con-
trols because of the presence of numerous polymor-
phisms. Novel primers were chosen, to exclude the poly-
morphic sequences within the PCR products of two
exons (exons 42 and 44). Although the amended am-
plification products do not completely cover the relevant
exons and their genomic flanking regions, they allowed
the detection of two novel band shifts.
A total of 16 sequence variants were identified (table
3). Five of these result in premature termination codons
or frameshifts and are potentially null mutations. An-
other is an 18-bp deletion in exon 20 and would be
expected to result in the deletion of two Gly-X-Y repeats.
Two other mutations affect splicing. One is a 46-bp de-
letion, which includes 17 bp of exon 15 and 29 bp from
the 5′ part of intron 15; the second is an ArG substi-
tution at position 23 in intron 45, which creates a
potential acceptor splice site. The presence of a potential
branch point at position 37 (GGTTTAAC) may allow
this cryptic splice site to be used, which leads to a
frameshifted transcript. This mutation was not found in
any of the 48 unrelated controls screened. Thus, all of
these mutations are expected to be pathogenic. Seven
further nucleotide differences cause presumptive amino
acid substitutions. One is a leucine for proline substi-
tution in the carboxyterminal NC1 domain, P1572L.
This change was not found in 48 control DNAs, involves
a proline conserved among all of the human type IV a
chains, and thus is probably pathogenic. All the other
amino acid substitutions occur in the collagenous do-
main. Four are substitutions of nonglycine residue. Two
of these, L1004P and P1402S, are obviously amino
acid–sequence polymorphisms, since their frequencies
are .46 and .68, respectively, in 90 normal chromosomes.
The other two, E570Q and A931T, do not involve con-
served amino acids. One, E570Q, is present in 1 of the
48 controls screened and therefore is likely not to be
pathogenic. A931T was not found in the control pop-
ulation, but, as this group does not adequately represent
the West Indian population from which the patient orig-
inates, its significance remains unclear. The last two var-
iants are glycine substitutions, G545A and G1030V,
within continuous stretches of Gly-X-Y repeats in the
collagenous domain. The glycine-to-valine substitution
was found in only one patient and in no control indi-
viduals. The alanine for glycine substitution, on the other
hand, was found to be homozygous in two unrelated
patients, both from consanguinous families, and was
also found to be heterozygous in one patient (family
AR12), in whom two nonsense mutations had already
been found, as well as in numerous control individuals.
In fact, 30 (11.5%) of 261 control individuals of various
geographic origins display the G545A substitution in the
heterozygous state. Interestingly, this number includes
15 (of 60) individuals originating from North Africa. In
addition, in one North African individual without any
obvious phenotype, G545A was present in the homo-
Table 1
COL4A4 Intron-Exon Boundaries
Exon
Number
Exon Size
(bp) 3′ Splice Site 5′ Splice Site
Intron
Number
Approximate
Intron Sizea
(kb)
1 178b CGTCCCCACAG gtaaggcgcccataggtggggcaaccgctg 1 5.4
2 172 tgttttaagtgatatatttatatctaacag GAACAGACTTT GGT CCC TG. gtgagtatcctcagtgtgattgcctgcttt 2 2.6
3 43 aaattaatctgcgtttttgtttttctgtag ..G TCA CTT GTA TAT GGG gtaagtacattcactagctctggttgcgtt 3 4.2
4 78 gtatactaaataagatgcttcactttccag AGT GGA AAG GGG TCT CGG gtaagtgatgtaaagaccaacatgggcagc 4 112
5 135 cccccatttctttttaatcttccttctcag GGT CCA CCA GGA GAT AAG gtaagccacatcttatgtggagattcacat 5 1
6 45 atctctttgttttattttctgggattttag GGT CCA ACT GGC ATA CCT gtaagtatccctaaattttctcccattttt 6 1.2
7 117 atgcttcacttataattttgttttctgcag GGG CAC CCA GGC CCC CTA gtaagatacccacagttcatcttaacagga 7 3.4
8 69 ctgttaagtacatacatattttattttcag GGC CAT CCT GGT ATT CAG gtaagtattatgatcatgatgggttaaaaa 8 2.8
9 36 acttaaagcgatgcattcttatttttgcag GGA GAC AGA GGC TTA CCA gtaagtctcctgagcaggctctatgcttct 9 2.5
10 63 aacagatgcactgatttttctcatgtttag GGA TCT TGG GGG TTA GTG gtaagtacagcactgctgatgtgatccctt 10 .355c
11 36 tgatttgtgtttttttctcccttgatttag GGA CCT CCG GGT TTG AAG gtaggcagtcatgagcaagatacatcaata 11 .210c
12 42 caattagattctttttcatttctttctcag GGA AAT CCC GGA GAC CCG gtaagaattccctcttgctctgaggagcaa 12 4.7
13 81 aattttcattatcttgcttttttttttaag GGT GAG GTT GGA GAA AAG gtaattcccaaatccatatgtcaccttgga 13 .7
14 54 agaccaaattatattcattgtaatttttag GGT ATA AAA GGA CGC AAG gtagtttatttaagtaccttttttttttca 14 .3
15 60 aacccctctaaatgttgtcatctcttaaag GGA GAA TCT GGG CCT CGG gtaagcatcatttgctgttaacatcagtga 15 .8
16 45 tgtttatcctgatttttgtgaatttattag GGG GAT CCT GGA TTA AAG gtaaatgtacctcattatagagataataaa 16 .308c
17 54 tttttaaggcatgtttgtgcttgtttgtag GGA GAA CTA GGC CCA AAG gtaaaaagtgagcctattttaatatatcct 17 1.8
18 70 tttaaaaagtgaatgaatgaatgatttcag GGG GAT CCT CTT AAA G.. gtttgtgttcctattcagttcctccataaa 18 .8
19 105 tttattctcatgtaccattatctttggcag .GC CCA CCA TGT GCA G.. gtacggatgccctgatgtgccctggctttt 19 4.3
20 165 tgtaattttcattcttgatttatcttgcag .GC ATG ATA TCA AGT G.. gtgaagtgcgccttattcatatccattagc 20 3.8
21 90 tctctgcccacccccttacctccttgacag .TG ATA TAC GAA AAA G.. gcaagtaggcaccaaaggtagaatttctag 21 .5
22 164 tgacaaatctgccattgatcctctgtctag .GA AAT GAA GGG CTA CCA gtgagtacctcttaccagtcatctttccag 22 6.8
23 73 cctaatttgtttctcttatttttcaccaag GGA AAG CAT GTT AAA G.. gtgagcataatcaatcacttaactccctgc 23 1.7
24 107 gcttgaatatcttttgacctctatttccag .GG CAC AAA GGA CCT CCA gtatgtagaattcttctcttgctatagaat 24 2.4
25 184 ggtaattgactcatgacataacattcccag GGG GAT CAT CAG AAA G.. gtaattttaaaaaaattttatttatttcaa 25 112
26 69 gtgaatgccgcttttcttttctcattgcag .GT GAC ACA CCT CCA G.. gtattatcaatgagaagttactgtcttata 26 2.7
(continued)
Table 1 (continued)
Exon
Number
Exon Size
(bp) 3′ Splice Site 5′ Splice Site
Intron
Number
Approximate
Intron Sizea
(kb)
27 108 agtctgtgttttgtttttattattgtttag .GT CCG AAG CCA CCT G.. gtcagtgaggtttttttttttttttttttt 27 .4
28 219 cattaaaaatttttttttgttgttaaatag .GT TTT CGT GCT GAA G.. gtatgagggctttgctgtccttttggtgca 28 1.6
29 162 gaatgtcatggatgtattgtatcatctcag .GG CCA GCT AGC CCA G.. gtaagtgtcaagaactgtgaagggtctggg 29 1.3
30 171 acacactgtggtcactgtggtttgtcttag .GT GCT CCA CCA AAG G.. gtaggtagtgctttttccatgatgtcctcc 30 .5
31 144 tcctaaaactttatgctctcatttcaccag .GA CCC CGG GCC AAA G.. gtaaataaaatacagccatgcaacatgcat 31 2
32 108 attttgttcttgcataattaatatccatag .GA GCC ATA GAA AGA G.. gtaaacacttaagagtttttaaccatatca 32 1.1
33 182 agagacctgtaacacttccaacttcatcag .GT GAT AAA GGT GAC CAG gtaaggggctactgctttgtgggggaagag 33 .9
34 64 ttaaggccttttgtttcattaaactgtcag GGT GAG CCA CCT AAA G.. gtatggtttggagatacagaagccatctgt 34 2.4
35 75 gtaatgtcacatgcattttatccctttcag .GA AAC AAA TGT CCA G.. gtatagctgcatatttttcttactaaaaca 35 4.7
36 108 aactctgatgtttgatctttccttctttag .GG CAT TTT TGC CCA G.. gtaccttgaaaggaaatctggagacttcct 36 .8
37 108 ccatctgcaaaacttccctgtcatcctcag .GT GAT CAC ATA AAA G.. gtaagtcaaaatgaagcccatcccacaaga 37 10.8
38 72 tttgggtcacaggcctgtggtgtttttcag .GT CCC TCC GCT TCA G.. gtaagcacctaatcgattcgtaacagactg 38 1.2
39 129 tatagtattaattctgttttccccattaag .GT TTG CAT CCC CCA G.. gtaagctgtagcatgctttgcccttctttc 39 .092c
40 111 aggataacatgtgaacatgtctcttcttag .GG AGT TCA CCA AGA G.. gtatgagagaatcatgacaaaggatggcag 40 1.3
41 156 agaatatttttgtctcttctctgtggtcag .GA GCA CCT CAG AAA G.. gtatgaatgttgttccgttaagtaatatgt 41 3
42 108 cctcatttttatgttttgtttttttttaag .GA CCA ATG CTT CCA G.. gtgagcttccaacctacatacagcattttg 42 2
43 9 gcctcgtttgttgtctttggatccctctag .GT CCC AGA G.. gtaagctttgctataaaattggtaatttcc 43 3.7
44 126 ccattacacaagcggtgattccaatttcag .GT GAA CCG GGA CCA G.. gtatgagccgcatgctgattgttcattatt 44 9
45 117 tcaccaccagcatcataaacttttgtgcag .GG TGC AAA GGA CCA G.. gtagagtttcagtcactcctcttttctctg 45 1.5
46 189 gccttcaatttttttcctttgttcctccag .GG CCT CCT GAC CTT G.. gtatggatacaggatcgcccatctccattg 46 1.7
47 287 acaccagctgtctcttcttcccttcccaag .GT CTG GCA TTC CTG ATG gtgagtcccgtgcccttgaaaaccctggct 47 .4
48 1264 agccctaattctctcttgttttctgggtag CAC ACA GGA
NOTE.—Sixty–base pair intronic sequences for each boundary have been deposited in European Molecular Biology Laboratory/GenBank.
a Intron sizes were determined from YAC DNA and may have been underestimated if internal deletions of the YAC have occurred.
b According to Momota et al. (1998).
c Exact intron size (obtained by sequencing).
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Figure 1 Comparison of exon sizes in the COL4A4 gene with the COL4A6 (Oohashi et al. 1995) and col4a2 (Buttice et al. 1989) genes.
Exon numbers are indicated by the numbers below each gene. Exons of conserved size between COL4A4 and either col4a2 or COL4A6 are
indicated in black, coding exons of differing sizes are indicated by open boxes. Noncoding regions are represented in gray.
zygous state. These data suggest that the G545A variant
has little or no functional significance and that substi-
tution of alanine for glycine at this position does not
cause any severe pathogenesis.
In total, 10 mutations that are likely to be pathogenic
were found in eight patients, with one nonsense muta-
tion being found in two unrelated patients. In three pa-
tients originating from consanguineous marriages, the
mutation, as expected, was homozygous. In three others,
both heterozygous mutations were found, and in two
cases, only one mutation was detected.
Segregation of the Mutations in the Families
In three families, one consanguineous (AR2), and in
two families in which both mutations were found in the
probands (AR18, AR23), the segregation of the muta-
tion could be studied (fig. 2). In family AR2, six indi-
viduals are homozygous for the mutation (fig. 2a), and
two patients each from families AR18 and AR23 (fig.
2b and c, respectively) share two different COL4A4 mu-
tations, one inherited from each parent. All of these pa-
tients have features of severe AS, including deafness. Five
of them, aged 22–34 years, already have end-stage renal
disease or chronic renal failure, and the five others, all
aged !28 years, present hematuria and proteinuria. In
these families, various members have permanent micro-
scopic hematuria. The individuals with hematuria all
have normal renal function (even at age 90 years), except
one (patient II.2 of family AR23), aged 54 years, whose
chronic renal failure might be the result of lithium ther-
apy. One individual (III.2 of family AR18) has both mi-
croscopic and episodes of macroscopic hematuria. A re-
nal biopsy performed in individual III.7 of family AR23
at age 27 years displayed thin basement membranes. All
hematuric individuals also display a COL4A4 mutation
in the heterozygous state, but not all individuals carrying
the same mutation seem to have microscopic hematuria;
however, the latter group tends to be younger than the
hematuric individuals.
Discussion
We report the complete intron-exon structure of the
human COL4A4 gene, which encodes the a4 chain of
type IV collagen. This gene had previously been mapped,
head-to-head with the COL4A3 gene, to chromosome
2q34-37 (Mariyama et al. 1992), and cDNAs had been
isolated covering the entire coding sequence (Leinonen
et al. 1994), but its genomic structure had not been
determined, with the exception of its 3′ end (Kamagata
et al. 1992; Sugimoto et al. 1993; Mochizuki et al.
1994). Using a combination of long-range PCR and li-
gation-mediated PCR, we amplified and sequenced
YACs covering the chromosomal region and searched
for deviations from the published cDNA sequence that
would indicate the presence of introns. By virtue of the
sizes of overlapping long range PCR products, using
YAC DNA as template, we can put the size of the
COL4A4 gene at a minimum of 113 kb. This estimate
does not take into account the sizes of introns 4 and 25,
which must be 112 kb, since we could not amplify them.
This large size is typical of the human type IV collagen
genes. With reference to the published cDNA sequence
(Leinonen et al. 1994), the COL4A4 gene was found to
have 48 exons, with a 5′ UTR covering exon 1 and part
of exon 2. Recently, Momota et al. (1998) further char-
acterized the transcription start site, increasing the size
of exon 1 to 178 bp, and described an alternative first
exon (exon 1′) with rather ubiquitous and low expres-
sion and located upstream of exon 1. Contrary to a
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Table 2
Oligonucleotide Primers and PCR Conditions Used for SSCP Analysis
Exon
Number
Sense (No. of Intron Bases between
Primer and Exon)
(5′r3′)
Antisense (No. of Intron Bases between
Primer and Exon)
(5′r3′)
PCR Annealing
Temperature
(C)
PCR Product
Size
(bp)
2 TCTGGAAGAGAAGACTGGCAa (32)b (10) AAGCAGGCAATCACACTGA 54 153
3 TGTTTAAATTAATCTGCGTT (15) (11) GCAACCAGAGCTAGTG 45 105
4 CGATGAGTACTGGTATACTA (22) (12) ATGCTGCCCATGTTGGTCTT 50 152
5 ACCCCCATTTCTTTTTAATC (11) (22) GGTGAGTCTTTCATGTGAAT 54 208
6 TCTCTTTGTTTTATTTTCTG (9) (33) GATGAGTACTTCTGCCTTTT 47 127
7 TTTCGCAAAAATGCTTCACT (20) (34) CCACAGGGCCTGTTCACTTA 50 211
8 TACTGAAATGGTAATACGCT (36) (39) CATGGGCTTACCTATTTGGA 48 184
9 TGTGTGGACTTAAAGCGATG (17) (3) TAGAGCCTGCTCAGGAGACT 53 96
10 TTGGGTAACAGATGCACTGA (16) (10) AAGGGATCACATCAGCAGTG 55 129
11 TTGTGTTTTTTTCTCCCTTG (5) (28) TTTCATTGTTCAGGGCTCTA 50 109
12 AGCCAGAAGTCTTAATTGCT (57) (17) TCACCATTTGCTCCTCAGAG 54 156
13 GGGTGGAAACCTTCAAAACA (43) (15) TACTTTCCAAGGTGACATAT 50 179
14 GGAGATGGAATTCAGTATGT (44) (59) AAAGACCATGAGAAATAACA 53 197
15 CCCCTCTAAATGTTGTCATC (8) (72) TTTGAGCTTGTGGGACTACT 54 180
16 AATGATGCACTGAGCTGGTT (49) (66) GCACGCAACAGTACAACTTC 53 200
17 ATTTGTCACCCCGTCACTTT (34) (73) GAATGATTCCTGGCAATACT 50 201
18 CCAGGCAACATGAGTAAAAT (39) (6) TGGAGGAACTGAATAGGAAC 50 155
19 TGCACATACCATTTGTTTAT (25) (5) CCAGGGCACATCAGGGCATC 50 175
20 TTCTTCTACAGAGACGTTT (44) (11) TGCTAATGGATATGAATAAG 52 259
21 TATAGAAGACAGTCAGAAAA (42) (9) TAGAAATTCTACCTTTGGTG 50 181
22 AAATATGACAAATCTGCCAT (15) (8) GGAAAGATGACTGGTAAGAG 50 227
23 TGATCCATCACAATTAACCT (29) (9) CAGGGAGTTAAGTGATTGAT 53 149
24 ACTTTACCCTCTGCTGATAA (32) (48) GGGAAATAGTTGTTTGTATG 50 223
25 GACATTCAGTGGTTGGTAAT (24) (33) TAAACACTTGTACCCCAAAG 57 280
26 TCAGTTATGTGAATGCCGCT (19) (19) TGGGAAGTATATAAGACAGT 50 147
27 TGAGTCTGTGTTTTGTTTTT (12) (5) AAAAAAAAAAACCTCAC 52 210
28 ATTGGTTCTATACTTGCACA (35) (14) TCTATGCACCAAAAGGACAG 54 309
29 TGGGCCATCTGTATAGTTTT (37) (30) TAATAGTAAGTAGGGTAAGC 57 269
30 GCCTTCACACACTGTGGTCA (16) (13) ATGGGAGGACATCATGGAAA 55 240
31 TCCTAAAACTTTATGCTCTC (10) (27) TCAAATACCAGAAACAAATG 53 221
32 CCTGTTCATTTTGTTCTTGC (17) (22) TGTCAACTTATTTGATATGG 57 187
33 TTTCAGCAGAGACCTGTAAC (17) (32) AAGAACAGAAAGGTTTTATT 52 271
34 GTTGTGCATGTGCCATTTGT (43) (9) GATGGCTTCTGTATCTCC 50 154
35 TGAGACCAAATTAAATTGTC (34) (80) TCATTGCCAGCTAGAAGTAA 52 210
36 CAAACGGCAACTCTGATGTT (18) (17) AGTGCTCAGGAAGTCTCCAG 55 183
37 TATCTGGCCATCTGCAAAAC (17) (8) TTGTGGGATGGGCTTCATTT 55 173
38 GCGTTTGTGGCTAGAGTGAG (49) (27) GAACCATGGACTGAAGCTCAG 57 190
39 AGGCACTATAACAGGGACAAGA (40) (45) GGAGTAACGTAAACCTTCCA 60 256
40 ACCTTCCAAATGCAATGAGG (27) (4) CATCCTTTGTCATGATTCTCTC 53 184
41 TTTTTGTCTCTTCTCTGTGG (4) (18) AGTTATTCACATATTACTTA 48 218
42 GCCCTCATTTTTATGTTTTG (12) (29) ATTTTAGTAAATGTTTAGAC
GTTGGAAGCTCACCTGGAAGc
50
54
190
153
43 GACTGGCCTCGTTTG (20) (114) TTAATATCCTTACAGCACCC 50 180
44 ATTACACAAGCGGTGATTCC (6) (39) AGAATTTCATTTCAGCAATA
TGGCTCCTTCTGGTCCTCTCc
50
56
214
118
45 CACCAGCATCATAAACTT (8) (23) AGGTTTACAGTGTCAGAGAA 53 186
46 AGTGCCAGAACAGAGGTGCT (61) (7) GGAGATGGGCGATCCTGTA 57 297
47 ACACCAGCTGTCTCTTCTTC (10) (19) TGAATGAGCCAGGGTTT 57 353
48 GTGTGTGTCTGAGCCCTAAT (20) TGGTGAATTTCGCATTCT 50 322
a Exonic sequences are underlined.
b No. of exon bases between primer and beginning of translation.
c Novel primer designed to exclude polymorphic sequences within the PCR product.
report by Sugimoto et al. (1993), our data show that
the entire 3′ untranslated region of COL4A4 lies in a
single exon (48), as do those of the other type IV collagen
genes. All of the exons have conventional GT-AG donor
and acceptor splice sites, except exon 21, which has a
donor site with GC instead of GT, confirmed by se-
quencing several human control DNAs. Although ex-
tremely rare, this 5′ splice site sequence has been de-
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Table 3
Characteristics of Nucleotide Variants Detected in the COL4A4 Gene
Mutation or Variant Nucleotide Effect on Coding Sequence Exon Family
Mutation
Statusa
Presence in
Control
Individualsa
Pathogenic mutations
Nonsense
R1377X CrT at 4337 ArgrStop at 1377 44 AR12 h NDb
AR18 h
C1641X CrA at 5131 CysrStop at 1641 48 AR12 h ND
Frameshift
1013/6insA Ins of A at 1013/6 Frameshift at Gly 270 13 AR18 h ND
Stop at 366
2009delC Del of C at 2009 Frameshift at Pro 601 24 AR30 H ND
Stop at 652
3854/6delG Del of G at 3854/6 Frameshift at Ser 1217 39 AR23 h ND
Stop at 1287
In-frame deletion
1527del18bp Del of 18 bp at 1527 Del of Pro-Gly-Lys-Pro- 20 AR23 h ND
Gly-Ala from Pro at 441
Splicing
1122del46bp Del of 46 bp at 1122 5′ splice site 15c AR2 H ND
4542-23ArG ArG at 4542-23 Novel splice site 46 AR4 H 0/48
Missense
Mutations in the NC1 domain
P1572L CrT at 4923 ProrLeu at 1572 47 AR25 h 0/48
Glycine substitution in the
collagenous domain
G1030V GrT at 3297 GlyrVal at 1030 33 AR22 h 0/48
Variants of unknown significance
Nonglycine substitutions in the
collagenous domain
E570Q ArG at 1917 GlurGln at 570 24 AR19 h 1h/48
A931T GrA at 2999 AlarThr at 931 31 AR7 H 0/48
Intronic variant
2925-5ArT ArT at 2925-5 3′ splice site 31 AR31 H 2h/48
Coding region polymorphisms
Glycine substitution in the
collagenous domain
G545A GrC at 1842 GlyrAla at 545 23 AR6 H 30h/261
AR9 H 1H/261
AR12 h
Nonglycine substitutions in the
collagenous domain
L1004P TrC at 3219 LeurPro at 1004 33 11H/45
19h/45
P1402S CrT at 4414 ProrSer at 1402 44 19H/42
19h/42
a H  homozygous change; h  heterozygous change.
b ND  not done.
c Deletes 17 bp of exon 14 and 29 bp in the 5′ part of intron 15, deleting the 5′ splice site.
scribed, elsewhere, for single exons in a few genes
(Senapathy et al. 1990) and, in particular, for COL4A1
exon 34 (Soininen et al. 1989).
Current knowledge of the type IV collagen gene family
indicates that these genes derive from a common ances-
tral gene (Zhou et al. 1994). By comparison of their
peptide sequences, as predicted from their cDNA se-
quences, the a chains can be divided into two classes by
virtue of their homology to either a1- or a2-like chains.
The deduced a4 chain was shown to belong to the a2-
like group (Leinonen et al. 1994) by virtue of homology
at the amino acid level; this is further supported here by
a high proportion of identical exon sizes and positions
of split glycine residues at exon-intron boundaries, com-
pared with human COL4A6 (Oohashi et al. 1995) and
mouse col4a2 (Buttice et al. 1990).
Having characterized the COL4A4 gene structure, we
performed mutation screening by SSCP in all COL4A4
coding exons of 31 patients with recessive AS, and we
detected 10 novel mutations that are likely to be caus-
Boye et al.: Genomic Structure of the COL4A4 Collagen Gene 1337
Figure 2 Mobility shifts observed in SSCP/heteroduplex analysis of DNA from members of three families. a, Family AR2, mutation
1122del46bp in exon 15. No clinical information or DNA samples were available for generations I and II. The uppermost bands, found only
in heterozygotes, represent heteroduplex products. b, Family AR18, upper SSCP panel, mutation 1013/6insA in exon 13, present in the two
siblings affected with autosomal recessive AS (IV.1 and IV.2) as well as in their mother; lower SSCP panel, mutation R1377X in exon 44,
present in the two affected children and in the paternal branch. c, Family AR23, upper SSCP panel, mutation 3854delG in exon 39, present
in the two children affected with autosomal recessive AS (III.1 and III.2) and in their father; lower SSCP panel, mutation 1527del18bp in exon
20, present in the two affected sibs as well as in their mother and several individuals from the maternal branch of the family. c indicates control
DNA; h, microscopic hematuria; h, no hematuria; h*, microscopic and episodes of macroscopic hematuria; h**, microscopic hematuria,
and thin basement membranes on renal biopsy; and ND, microscopic hematuria not determined.
ative and six different probably nonpathogenic amino
acid substitutions. Only two mutations in COL4A4 have
been described, to date, in autosomal recessive AS
(Mochizuki et al. 1994). The pathogenic mutations were
detected in eight unrelated families, including two non-
consanguinous families, in which only one heterozygous
mutation was detected. This represents a relatively low
mutation-detection rate compared with the 85% detec-
tion rate obtained in this laboratory using the identical
method in the screening of the cystinosis gene (G. Jean,
personal communication). It is possible that some
COL4A4 mutations have been missed because of the
presence of numerous polymorphisms that render the
detection of additional bandshifts very difficult. Of
course, mutations of the COL4A3 gene may also be
responsible for the disease in a significant number of
these patients. A further consideration is the possibility
that autosomal recessive AS can exist as a “digenic”
disease (i.e., with a COL4A4 mutation at one allele and
a COL4A3 mutation at the other). This could account
for the missing mutations in the two patients in whom
only one mutation was found. This question cannot be
addressed properly until the COL4A3 gene has been
fully characterized and comprehensively screened in this
and other patient cohorts.
Two mutations detected were glycine substitutions,
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G545A and G1030V, which would be predicted to in-
terrupt the Gly-X-Y repeat stretches in the collagenous
domain. The G1030V mutation was not found in any
controls and thus was considered likely to be pathogenic.
In contrast, and rather suprisingly, we found the G545A
variant in a patient with two nonsense mutations, as
well as in a large number of control individuals, which
excluded the possibility that it is responsible for the phe-
notype. Moreover, we found a control individual with
this substitution in the homozygous state. This is the
first description of a homozygous glycine substitution in
a collagen chain that does not produce any obvious phe-
notype. The small size of the glycine residue, due to the
absence of a side chain, is critical for the formation of
a stable collagen triple helix. Although alanine is a bulk-
ier and more hydrophobic amino acid, structurally, it is
the most similar to glycine, and its substitution would
thus be predicted to produce the most minimal disrup-
tion of the helix. This could explain why glycine-to-
alanine substitutions in the collagenous domain are less
frequent than other glycine substitutions, as is observed
in severe forms of osteogenesis imperfecta (Byers and al.
1991) and in X-linked AS (3 of 69 glycine substitutions
reported in the Human Gene Mutation Database Car-
diff; Krawczak and Cooper 1997). Furthermore, type IV
collagens contain numerous interruptions in the collag-
enous regions and thus might be likely to tolerate glycine
substitutions at particular sites in the gene. The glycine
at position 545 is located in a stretch of two Gly-X-Y
triplets that lack prolines (in the X and Y positions)
thought to be essential for thermostability (Westerhau-
sen et al. 1990). This could suggest that local stability
of this region is not critical to overall stability of the
helix, so that disruption here does not significantly affect
protein structure, folding, or function.
Given the frequency of this mutation in the popula-
tion, it should be present in ∼1/300 individuals in the
homozygous state. One could therefore speculate that
the latter group represents sporadic cases of microscopic
hematuria, which seems to be relatively frequent in the
general population (Cameron 1998) and would gener-
ally escape detailed molecular investigation.
In one family, the mutation 1527del18bp segregates
with the presence of microscopic hematuria and thin
basement membranes, typical features of familial benign
hematuria. Although one COL4A4 mutation has already
been described in a family with familial benign hema-
turia (Lemmink et al. 1996), this is the first report of a
type IV collagen mutation in a family showing the com-
plete clinical and histological features of FBH. Our re-
sults confirm that carriers of autosomal recessive AS may
have FBH, as suggested by Lemmink et al. (1996).
In this study, the elucidation of the COL4A4 genomic
structure enabled us to perform a comprehensive mu-
tation screen of the gene in 31 patients with autosomal
recessive AS and to detect 10 mutations in eight patients.
All of these mutations are likely to be causative, as they
can be predicted to alter the putative protein structure
significantly. These data, which document potentially
pathogenic COL4A4 mutations in AS and FBH and the
presence of glycine substitutions in the general popu-
lation, will contribute to genotype-phenotype correla-
tion studies and, along with the possibility of the exis-
tence of compound heterozygotes with mutations in
COL4A3 as well, will enhance arguments for including
those syndromes in a more generalized framework of
type IV collagen disorders.
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